Not found

Jianguo Wen, PhD

Assistant Research Professor of Pathology and Genomic Medicine, Institute for Academic Medicine
Assistant Research Member, Research Institute
Houston Methodist


Dr. Jianguo Wen earned his Ph.D. in Genetics from Fudan University in 2004. He joined Houston Methodist Research Institute in 2005 and completed his postdoctoral training in the Department of Pathology.

Description of Research

Dr. Wen’s research program focuses on pathogenesis and preclinical treatment of multiple myeloma. Current research efforts aim to develop therapies targeting multiple myeloma cancer stem cells.

Areas Of Expertise

Cancer Stem cells Multiple myeloma
Education & Training

Postdoctoral Fellowship, Houston Methodist Research Institute
PhD, Fudan University
MS, Northwest Sci-Tec University of Agriculture and Forestry, Shaanxi

Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy
Yang, S, Wen, J, Li, H, Xu, L, Liu, Y, Zhao, N, Zeng, Z, Qi, J, Jiang, W, Han, W & Zu, Y 2019, Small.

Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades
Sun, T, Wang, S, Sun, H, Wen, J, An, G & Li, J 2018, Leukemia and Lymphoma, vol. 59, no. 1, pp. 49-58.

Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing
Wen, J, Tao, W, Hao, S & Zu, Y 2017, Journal of Hematology and Oncology, vol. 10, no. 1, 119.

Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy
Li, H, Yang, S, Yu, G, Shen, L, Fan, J, Xu, L, Zhang, H, Zhao, N, Zeng, Z, Hu, T, Wen, J & Zu, Y 2017, Theranostics, vol. 7, no. 5, pp. 1204-1213.

SsDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 Cells
Yu, G, Li, H, Yang, S, Wen, J, Niu, J & Zu, Y 2016, PLoS ONE, vol. 11, no. 1, e0147674.

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen, J, Tao, W, Hao, S, Iyer, SP & Zu, Y 2016, Leukemia, vol. 30, no. 4, pp. 987-91.

Utilizing a high-throughput microfluidic platform to study hypoxia-driven mesenchymal-mode cell migration
Zhang, Y, Wen, J, Zhou, L & Qin, L 2015, Integrative Biology (United Kingdom), vol. 7, no. 6, pp. 672-680.

Mutated genes and driver pathways involved in myelodysplastic syndromes - a transcriptome sequencing based approach
Liu, L, Wang, H, Wen, J, Tseng, CE, Zu, Y, Chang, CC & Zhou, X 2015, Molecular BioSystems, vol. 11, no. 8, pp. 2158-2166.

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions
Wen, J, Tao, W, Kuiatse, I, Lin, P, Feng, Y, Jones, RJ, Orlowski, RZ & Zu, Y 2015, International Journal of Cancer, vol. 136, no. 5, pp. 991-1002.

SDF-1a stiffens myeloma Bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II
Choi, DS, Stark, DJ, Raphael, RM, Wen, J, Su, J, Zhou, X, Chang, CC & Zu, Y 2015, International Journal of Cancer, vol. 136, no. 5, pp. E219-E229.

Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach
Peng, H, Peng, T, Wen, J, Engler, DA, Matsunami, RK, Su, J, Zhang, L, Chang, CC & Zhou, X 2014, Bioinformatics, vol. 30, no. 13, pp. 1899-1907.

Targeting the biophysical properties of the myeloma initiating cell niches: A pharmaceutical synergism analysis using multi-scale agent-based modeling
Su, J, Zhang, L, Zhang, W, Choi, DS, Wen, J, Jiang, B, Chang, CC & Zhou, X 2014, PLoS ONE, vol. 9, no. 1, e85059.

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells
Wen, J, Li, H, Tao, W, Savoldo, B, Foglesong, JA, King, LC, Zu, Y & Chang, CC 2014, British Journal of Haematology, vol. 166, no. 5, pp. 711-719.

Discovering transcription and splicing networks in myelodysplastic syndromes
Wang, H, Wen, J, Chang, CC & Zhou, X 2013, PLoS ONE, vol. 8, no. 11, e79118.

Biostable ssDNA aptamers specific for Hodgkin lymphoma.
Parekh, P, Kamble, S, Zhao, N, Zeng, Z, Wen, J, Yuan, B & Zu, Y 2013, Sensors (Basel, Switzerland), vol. 13, no. 11, pp. 14543-14557.

Cancer stem cells: A review of potential clinical applications
Podberezin, M, Wen, J & Chang, CC 2013, Archives of Pathology and Laboratory Medicine, vol. 137, no. 8, pp. 1111-1116.

Research article: Monitoring the progression of metastatic breast cancer on nanoporous silica chips
Fan, J, Deng, X, Gallagher, JW, Huang, H, Huang, Y, Wen, J, Ferrari, M, Shen, H & Hu, Y 2012, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol. 370, no. 1967, pp. 2433-2447.

Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system
McGowan, P, Nelles, N, Wimmer, J, Williams, D, Wen, J, Li, M, Ewton, AA, Curry, C, Zu, Y, Sheehan, A & Chang, CC 2012, American journal of clinical pathology, vol. 137, no. 4, pp. 665-670.

A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes
Peng, H, Wen, J, Zhang, L, Li, H, Chang, CC, Zu, Y & Zhou, X 2012, Molecular BioSystems, vol. 8, no. 4, pp. 1366-1374.

Selective gene transfection of individual cells in vitro with plasmonic nanobubbles
Lukianova-Hleb, EY, Samaniego, AP, Wen, J, Metelitsa, LS, Chang, CC & Lapotko, DO 2011, Journal of Controlled Release, vol. 152, no. 2, pp. 286-293.

Live Chat Available